Nanobody as a New Generation of Functional Proteins Nanobody as a new functional domains
Iranian Journal of Pharmaceutical Sciences,
دوره 14 شماره 3 (2018),
1 July 2018
,
صفحه 91-106
https://doi.org/10.22037/ijps.v14.40650
چکیده
Nanobody (Nb) or VHH is the smallest binding domain of camelid heavy chain antibody (HcAb). Light chains of HcAb naturally removed and because of some evolutionary changes, Nbs have unique properties rather than conventional antibodies. The size of Nb is about one-tenth (0.1) of whole antibodies and this size improved some problems of four chains antibodies such as high yield of expression in prokaryotic systems and penetration to tissues. Some other characteristics of Nb like close homology to human VH, high stability in the extended range of pH and temperature, and the capability to the identification of unusual epitope are very attractive for research and development of new Nb candidates for diagnosis, research, and therapeutic applications. Discovery of Nb almost coincided with advancement in phage display technology that was used along with Hybridoma technology in monoclonal antibody development. Currently, many of research groups focused on high-quality Nbs development against different targets especially in cancers and fortunately there are many of Nbs in clinical trial stages for use in extended ranges of diseases such as cancers, autoimmune, inflammatory diseases, and infectious diseases. Recently two of them were approved for clinical use. Big companies like Ablynx and Merck have been invested in this field and in future, further drugs base Nbs were approved in different areas of health science. In this review, we focused on production, features, and clinical application of Nbs and will be noted to Nbs in clinical trials.
- Monoclonal antibodies
- Phage display
- Camel heavy chain antibody
- Nanobody/ (VHH)
- Cancer
ارجاع به مقاله
مراجع
[2] Rodgers KR, Chou RC. Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions. Biotechnology advances. 2016;34[6]:1149-58.
[3] Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology. 1995;105[1]:23-9.
[4] Ecker DM, Jones SD, Levine HL, editors. The therapeutic monoclonal antibody market. MAbs; 2015: Taylor & Francis.
[5] Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery. 2017;16[5]:315-37.
[6] Larrick JW, Alfenito MR, Scott JK, Parren PW, Burton DR, Bradbury AR, et al., editors. Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA. MAbs; 2016: Taylor & Francis.
[7] Spadiut O, Capone S, Krainer F, Glieder A, Herwig C. Microbials for the production of monoclonal antibodies and antibody fragments. Trends in biotechnology. 2014;32[1]:54-60.
[8] Kolkman JA, Law DA. Nanobodies–from llamas to therapeutic proteins. Drug Discovery Today: Technologies. 2010;7[2]:e139-e46.
[9] Bever CS, Dong J-X, Vasylieva N, Barnych B, Cui Y, Xu Z-L, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Analytical and bioanalytical chemistry. 2016;408[22]:5985-6002.
[10] Cui H, Wang Q. Progress in single-domain antibody derived from heavy-chain antibody. Sheng wu gong cheng xue bao= Chinese journal of biotechnology. 2005;21[3]:497-501.
[11] Alibakhshi A, Kahaki FA, Ahangarzadeh S, Yaghoobi H, Yarian F, Arezumand R, et al. Targeted cancer therapy through antibody fragments-decorated nanomedicines. Journal of Controlled Release. 2017;268:323-34.
[12] Helma J, Cardoso MC, Muyldermans S, Leonhardt H. Nanobodies and recombinant binders in cell biology. J Cell Biol. 2015;209[5]:633-44.
[13] Klarenbeek A, Mazouari KE, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, et al., editors. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. MAbs; 2015: Taylor & Francis.
[14] Noël F, Malpertuy A, de Brevern AG. Global analysis of VHHs framework regions with a structural alphabet. Biochimie. 2016;131:11-9.
[15] Escher D. Acceptor framework for CDR grafting. Google Patents; 2015.
[16] Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. 2009;284[5]:3273-84. Epub 2008/11/18.
[17] Koromyslova AD, Hansman GS. Nanobody binding to a conserved epitope promotes norovirus particle disassembly. Journal of virology. 2015;89[5]:2718-30.
[18] Pleiner T, Bates M, Trakhanov S, Lee C-T, Schliep JE, Chug H, et al. Nanobodies: site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation. Elife. 2015;4:e11349.
[19] Hoefman S, Ottevaere I, Baumeister J, Sargentini-Maier ML. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended Nanobodies®. Antibodies. 2015;4[3]:141-56.
[20] Könning D, Zielonka S, Grzeschik J, Empting M, Valldorf B, Krah S, et al. Camelid and shark single domain antibodies: structural features and therapeutic potential. Current opinion in structural biology. 2017;45:10-6.
[21] Van Heeke G, Allosery K, De Brabandere V, De Smedt T, Detalle L, de Fougerolles A. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacology & therapeutics. 2017;169:47-56.
[22] MARIOTTI M. Investigation of interactions between nanobodies and their antigens using SPR detection methods.
[23] Yan J, Li G, Hu Y, Ou W, Wan Y. Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications. Journal of translational medicine. 2014;12[1]:343.
[24] Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A, et al. NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife. 2016;5. Epub 2016/07/20.
[25] Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Frontiers in immunology. 2017;8.
[26] Fridy PC, Thompson MK, Ketaren NE, Rout MP. Engineered high-affinity nanobodies recognizing staphylococcal protein a and suitable for native isolation of protein complexes. Analytical biochemistry. 2015;477:92-4.
[27] Tong Q, Zheng L, Zhao R, Xing T, Li Y, Lin T, et al. Human papillomavirus infection mechanism and vaccine of vulva carcinoma. Open Life Sciences. 2016;11[1]:185-90.
[28] Boons E, Li G, Vanstreels E, Vercruysse T, Pannecouque C, Vandamme A-M, et al. A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity. Antiviral research. 2014;112:91-102.
[29] Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrobial agents and chemotherapy. 2016;60[1]:6-13.
[30] Günaydın G, Yu S, Gräslund T, Hammarström L, Marcotte H. Fusion of the mouse IgG1 Fc domain to the VHH fragment [ARP1] enhances protection in a mouse model of rotavirus. Scientific reports. 2016;6:30171.
[31] Obishakin E, Stijlemans B, Santi-Rocca J, Vandenberghe I, Devreese B, Muldermans S, et al. Generation of a nanobody targeting the paraflagellar rod protein of trypanosomes. PloS one. 2014;9[12]:e115893.
[32] Hufton SE, Risley P, Ball CR, Major D, Engelhardt OG, Poole S. The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. PloS one. 2014;9[8]:e103294.
[33] Tarr AW, Lafaye P, Meredith L, Damier‐Piolle L, Urbanowicz RA, Meola A, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission. Hepatology. 2013;58[3]:932-9.
[34] Moonens K, De Kerpel M, Coddens A, Cox E, Pardon E, Remaut H, et al. Nanobody mediated inhibition of attachment of F18 fimbriae expressing Escherichia coli. PloS one. 2014;9[12]:e114691.
[35] McLean R. Heterologous expression and secretion of nanobodies targeting Campylobacter jejuni for intestinal health applications: Lethbridge, Alta: University of Lethbridge, Dept. of Chemistry and Biochemistry; 2016.
[36] Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Medical microbiology and immunology. 2009;198[3]:157-74.
[37] De Vooght L, Caljon G, Stijlemans B, De Baetselier P, Coosemans M, Van Den Abbeele J. Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microbial cell factories. 2012;11[1]:23.
[38] Ardekani LS, Gargari SLM, Rasooli I, Bazl MR, Mohammadi M, Ebrahimizadeh W, et al. A novel nanobody against urease activity of Helicobacter pylori. International Journal of Infectious Diseases. 2013;17[9]:e723-e8.
[39] Stijlemans B, Caljon G, Natesan SKA, Saerens D, Conrath K, Pérez-Morga D, et al. High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS pathogens. 2011;7[6]:e1002072.
[40] Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature medicine. 2006;12[5]:580-4.
[41] Khamrui S, Turley S, Pardon E, Steyaert J, Fan E, Verlinde CL, et al. The structure of the D3 domain of Plasmodium falciparum myosin tail interacting protein MTIP in complex with a nanobody. Molecular and biochemical parasitology. 2013;190[2]:87-91.
[42] Allocca M, Jovani M, Fiorino G, Schreiber S, Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. Current drug targets. 2013;14[12]:1508-21.
[43] Krah S, Schröter C, Zielonka S, Empting M, Valldorf B, Kolmar H. Single-domain antibodies for biomedical applications. Immunopharmacology and immunotoxicology. 2016;38[1]:21-8.
[44] Vanheusden K, Detalle L, Hemeryck A, Vicari A, Grenningloh R, Poelmans S, et al., editors. PRE-CLINICAL PROOF-OF-CONCEPT OF ALX-0761, A NANOBODY® NEUTRALIZING BOTH IL-17A AND F IN A CYNOMOLGUS MONKEY COLLAGEN INDUCED ARTHRITIS MODEL. ARTHRITIS AND RHEUMATISM; 2013: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
[45] Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Molecular pharmacology. 2015;87[2]:251-62.
[46] Rinaldi M, Denayer T, Thiolloy S, Tosar LCP, Buyse M-A, De Decker P, et al. ALX-0962, an anti-IgE Nanobody® with a dual mode of action. Eur Respiratory Soc; 2013.
[47] Morais M, Cantante C, Gano L, Santos I, Lourenço S, Santos C, et al. Biodistribution of a 67 Ga-labeled anti-TNF VHH single-domain antibody containing a bacterial albumin-binding domain [Zag]. Nuclear medicine and biology. 2014;41:e44-e8.
[48] Steeland S, Puimège L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. Journal of Biological Chemistry. 2015;290[7]:4022-37.
[49] Libert C, Dejonckheere E. Mmp8 inactivating antigen binding proteins. Google Patents; 2011.
[50] Ragheb R, Sefid F, Baharie B, Saeidjavan V, Akhgari S, Emamian N, et al. HOMOLOGY MODELING AND TOPOLOGY PREDICTION OF FRPBPROTEININ NEISSERIA MENINGITIDIS. Journal of Fundamental and Applied Sciences. 2016;8[2S]:3578-90.
[51] Li H, Sun Y, Elseviers J, Muyldermans S, Liu S, Wan Y. A nanobody-based electrochemiluminescent immunosensor for sensitive detection of human procalcitonin. Analyst. 2014;139[15]:3718-21.
[52] Unciti-Broceta JD, Del Castillo T, Soriano M, Magez S, Garcia-Salcedo JA. Novel therapy based on camelid nanobodies. Therapeutic delivery. 2013;4[10]:1321-36.
[53] Van Hoorick D, Depla E, Verdonck FKD, Delanote V, Janssen D, Descamps F, et al. Kv1. 3 binding immunoglobulins. Google Patents; 2015.
[54] Amoozgar Z, Goldberg MS. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. Advanced drug delivery reviews. 2015;91:38-51.
[55] Arezumand R, Alibakhshi A, Ranjbari J, Ramazani A, Muyldermans S. Nanobodies as novel agents for targeting angiogenesis in solid cancers. Frontiers in immunology. 2017;8.
[56] Arezumand R, Mahdian R, Zeinali S, Hassanzadeh-Ghassabeh G, Mansouri K, Khanahmad H, et al. Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis. Molecular immunology. 2016;78:183-92. Epub 2016/09/21.
[57] Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, et al. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Molecular immunology. 2012;50[1-2]:35-41. Epub 2012/01/03.
[58] Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, et al. CXCR4 nanobodies [VHH-based single variable domains] potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proceedings of the National Academy of Sciences. 2010;107[47]:20565-70.
[59] Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, et al. A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth. International journal of cancer. 2011;129[8]:2013-24.
[60] Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y, et al. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics. 2015;5[4]:378.
[61] Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, et al. Anti‐c‐MET Nanobody®–a new potential drug in multiple myeloma treatment. European journal of haematology. 2013;91[5]:399-410.
[62] Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, et al. Llama-derived single variable domains [nanobodies] directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. Journal of Biological Chemistry. 2013;288[41]:29562-72.
[63] Van Impe K, Bethuyne J, Cool S, Impens F, Ruano-Gallego D, De Wever O, et al. A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Research. 2013;15[6]:R116.
[64] McMurphy T, Xiao R, Magee D, Slater A, Zabeau L, Tavernier J, et al. The anti-tumor activity of a neutralizing nanobody targeting leptin receptor in a mouse model of melanoma. PloS one. 2014;9[2]:e89895.
[65] Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England journal of medicine. 2004;350[23]:2335-42.
[66] Jovčevska I, Zupanec N, Kočevar N, Cesselli D, Podergajs N, Stokin CL, et al. TRIM28 and β-Actin Identified via Nanobody-Based Reverse Proteomics Approach as Possible Human Glioblastoma Biomarkers. PloS one. 2014;9[11]:e113688.
[67] Behdani M, Zeinali S, Karimipour M, Khanahmad H, Schoonooghe S, Aslemarz A, et al. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New biotechnology. 2013;30[2]:205-9.
[68] Fang T, Duarte JN, Ling J, Li Z, Guzman JS, Ploegh HL. Structurally Defined αMHC‐II Nanobody–Drug Conjugates: A Therapeutic and Imaging System for B‐Cell Lymphoma. Angewandte Chemie International Edition. 2016;55[7]:2416-20.
[69] Gainkam LOT, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. Journal of Nuclear Medicine. 2008;49[5]:788-95.
[70] Xavier C, Blykers A, Vaneycken I, D'Huyvetter M, Heemskerk J, Lahoutte T, et al. 18 F-nanobody for PET imaging of HER2 overexpressing tumors. Nuclear medicine and biology. 2016;43[4]:247-52.
[71] Chakravarty R, Goel S, Cai W. Nanobody: the ―magic bullet‖ for molecular imaging? Theranostics. 2014;4[4]:386.
[72] De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends in biotechnology. 2014;32[5]:263-70.
[73] Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J Cell Biol. 2005;168[6]:863-8.
[74] Böldicke T, Weber H, Mueller PP, Barleon B, Bernal M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 [VEGFR-2/KDR]. Journal of immunological methods. 2005;300[1]:146-59.
[75] Marschall AL, Dübel S, Böldicke T. Recent advances with ER targeted intrabodies. Protein Targeting Compounds: Springer; 2016. p. 77-93.
[76] Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, et al. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Molecular Medicine. 1997;3[2]:96.
[77] Mukhtar MM, Li S, Li W, Wan T, Mu Y, Wei W, et al. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. The international journal of biochemistry & cell biology. 2009;41[3]:554-60.
[78] Swan C, Bühler B, Tschan M, Barbas Cr, Torbett B. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene therapy. 2006;13[20]:1480-92.
[79] Ma W-F, Du J, Fu L-P, Fang R, Chen H-Y, Cai S-H. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis. Molecular Cancer Research. 2009;7[10]:1613-21.
[80] Beyer F, Doebis C, Busch A, Ritter T, Mhashilkar A, Marasco WM, et al. Decline of surface MHC I by adenoviral gene transfer of anti‐MHC I intrabodies in human endothelial cells—new perspectives for the generation of universal donor cells for tissue transplantation. The journal of gene medicine. 2004;6[6]:616-23.
[81] Sangboonruang S, Thammasit P, Intasai N, Kasinrerk W, Tayapiwatana C, Tragoolpua K. EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2. Cancer gene therapy. 2014;21[6]:246-55.
[82] Marschall AL, Single FN, Schlarmann K, Bosio A, Strebe N, van den Heuvel J, et al., editors. Functional knock down of VCAM1 in mice mediated by endoplasmatic reticulum retained intrabodies. MAbs; 2014: Taylor & Francis.
[83] Mhashilkar AM, Lavecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, et al. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Human gene therapy. 1999;10[9]:1453-67.
[84] Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Molecular Therapy. 2005;12[3]:394-401.
- چکیده مشاهده شده: 130 بار
- IJPS_Volume 14_Issue 3_Pages 91-106 (English) دانلود شده: 28 بار